Y-mAbs amends IPO

Cancer company Y-mAbs Therapeutics Inc. (New York, N.Y.) amended its proposed NASDAQ IPO on Sept. 7 and now plans to sell 5.3 million shares at $14-$16. The offering is being underwritten by BofA Merrill Lynch, Cowen, Canaccord Genuity and BTIG.

At the $15 midpoint of its proposed range, Y-mAbs would raise $80 million and would be valued at $489.4 million...